The Academy of Physicians in Clinical Research Board of Trustees has the responsibility to support the organization’s mission and vision, serve as strategic decision-makers, and holds the legal authority of its organization. The Board governs the objectives and purposes of APCR which include (i) enhancing further the organization’s value proposition to its members through advocacy, competency and exchange, (ii) representing physicians directly or indirectly involved in clinical research endeavors, (iii) enhancing the proficiency of physicians directly or indirectly involved in clinical research endeavors, (iv) promoting the acquisition and dissemination of knowledge concerning therapeutic action, investigation, and development of pharmaceuticals, biologics, medical devices, and diagnostics, and (v) protecting the welfare of patients and study subjects. Trustees are elected from the APCR membership and the ACRP Nominating Committee is charged, by the APCR Board, with leading the recruitment process for qualified candidates.
Michael Koren, MD, FACC, FAPCR, CPI
Dr. Koren directs activities at Jacksonville Center for Clinical Research (JCCR), a multispecialty research organization with eight locations that has conducted more than 1,500 trials involving over 100 investigators. He also is a practicing cardiologist with the Apex Cardiovascular Group. Dr. Koren is an honors graduate of Brandeis University and Harvard Medical School. During his medical school training, he completed additional course work at the Harvard School for Public Health and wrote an M.D. thesis involving computer decision analysis. More recently he was awarded a US patent for developing the software system Ask100Doctors. Dr. Koren received his postdoctoral training at New York Hospital/ Memorial Sloan-Kettering Cancer Center/ Cornell University Medical Center in internal medicine and cardiology. During his postdoctoral training, Dr. Koren served as a third-year chief resident, held a faculty position and published several papers and abstracts. In recent years, he has served as the international lead principal investigator for several large multiple centered trials including ALLIANCE (a pivotal statin study), ROLE (ranolazine safety study), MENDEL (evolocumab) and OSLER (evolocumab). His scientific work, numbering over 100 abstracts and manuscripts, has been published in leading medical journals such as the Journal of the American College of Cardiology, New England Journal of Medicine, Postgraduate Medicine, and The Lancet. Dr. Koren has become interested in “the research of research.” He has presented abstracts on this subject at national meetings and served as a Past President and Board Member for the Academy of Physicians in Clinical Research (APCR) and twice as co-chair of the Ponte Vedra Cardiovascular Symposium. He serves on the Leadership Council of the Society of Clinical Research Sites (SCRS) and is President-elect of the First Coast Metro Board of the American Heart Association.
Cara East, MD, FAPCR
Dr. East has been involved in clinical trial research since 1987, working as a principal investigator for over 70 trials. She has also participated as a subinvestigator in more than 20 trials. Such studies have included the use of stem cells in cardiomyopathy and as an adjunct to heart surgery, studies of renal artery nerve ablation as an alternative treatment for hypertension, the use of mipomersen and the PCSK9 inhibitors in familial hypercholesterolemia, the development of novel oral anticoagulants for the prevention of thromboembolic events in atrial fibrillation, the need for repeat ablation following cryoablation for atrial fibrillation, and the gender of authors in a local journal. She has over 48 articles published in peer-reviewed journals and serves as a reviewer for several journals. She is currently a clinical professor at Texas A&M College of Medicine and a cardiology staff attending for Baylor University Medical Center Internal Medicine teaching program. She served on a general medicine IRB and as the cardiologist on an oncology IRB. She currently is a National Leader of the Paradise trial and is the chairman of the Data Safety Monitoring Committee for the NIH trial “Exercise and intensive vascular risk reduction in preventing dementia.”
IMMEDIATE PAST PRESIDENT
Andras Koser, MD, MBA, FAPCR, CPI
After graduating Summa cum Laude from Uzhgorod National University Medical School in 1981 in Uzhgorod, Ukraine, Andras Koser, MD became a medical director of a rural medical clinic in Ukraine. In 1987 Dr. Koser became a hospitalist in a community hospital, in Vac, Hungary and also started a private internal medicine practice. In 1991, Dr. Koser was offered a position of cardiovascular toxicologist for preclinical pharmaceutical research at White Eagle Laboratories, in Doylestown, PA. He completed residency training in Internal Medicine in 1997 and started working at Piedmont Internal Medicine in Spartanburg, South Carolina. In 2001 Dr. Koser became the founder and the medical director of a hospitalist group at Spartanburg Regional Hospital. In 2008 he founded a private hospitalist group that provided internal medicine care for patients at Carolina Medical Center in Gaffney and Chester Regional Medical Center. Beginning from his career in Hungary, Dr. Koser was always involved in pharmaceutical research initially as a Sub investigator and for the last 13 years as a Principal Investigator. He was the founder of multiple clinical research sites in upstate South Carolina and also in North Carolina. Dr. Koser has been the Principal Investigator for more than 130 pharmaceutical trials in multiple therapeutic areas. He is Board Certified in Internal Medicine and is a Certified Physician Investigator.
Daniel Weiss, MD, FAPCR, CPI
Dr. Weiss is a Medical Director with Celgene’s hematology/oncology pediatric drug development team. In this role he conducts clinical research in pediatric leukemias and brain tumors. Prior to his current role, Dan was Associate Director, Clinical Pharmacology at Celgene serving in the capacity of Clinical Research Physician, Medical Monitor and Clinical Pharmacologist. Dan is board certified in Emergency Medicine and prior to joining Celgene, he practiced as an attending emergency room physician at JFK Medical Center in Edison, NJ and Trinitas Hospital in Elizabeth, NJ. He also served as a Principal Investigator for MDS/Celerion at their dedicated Phase 1 clinical pharmacology unit in Neptune, NJ. Dan obtained his medical degree at Rutgers - New Jersey Medical School in Newark, NJ (formally University of Medicine and Dentistry of New Jersey) and completed his Emergency Medicine residency at Drexel University College of Medicine, Philadelphia, PA. Dan has a passion for clinical research and is a Certified Principal Investigator (CPI). When not at work, he can be found at the Jersey Shore making repairs to his 100 year-old home, bathing in the sun at Seven President’s Beach or surf fishing for striped bass!
Lyndon Mansfield, MD, FAPCR, CPI
Dr. Mansfield is a Certified Principal Investigator and is also Board Certified in Allergy/Immunology, Diagnostic Clinical Laboratory Immunology and Pediatrics. He has been involved in clinical research for over 30 years. Most of this research was on Asthma, COPD, Rhinitis, Urticaria, Atopic Dermatitis and Food Allergy. He has participated in over 312 clinical research protocols, has authored or co-authored over 100 medical manuscripts and over 115 scientific research presentations.
William Berger, MD, MBA, FAPCR
Ricardo Correa Marquez, MD, Es.D, FAPCR
Peter Rheinstein, MD, JD, MS, FAPCR
Harry Sarles, MD, FAPCR
Samuel Simha, MD, FAPCR
Michael Ybarra, MD, FAPCR